- Home
- CNTX vs SGMO Comparison
CNTX vs SGMO Comparison
Compare CNTX & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | SGMO |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.3M | 131.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CNTX | SGMO |
|---|---|---|
| Price | $2.26 | $0.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $6.00 | $5.75 |
| AVG Volume (30 Days) | 2.2M | ★ 8.0M |
| Earning Date | 03-19-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,875,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $0.35 |
| 52 Week High | $2.85 | $1.40 |
Technical Indicators
Market Signals| Indicator | CNTX | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 42.01 |
| Support Level | $2.06 | $0.35 |
| Resistance Level | $2.85 | $0.60 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 57.53 | 5.29 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.